MGNX
MacroGenics, Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 2,
"returned": 2,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "67a56fa7-d2a4-46eb-b884-7259953bf03f",
"title": "Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024",
"description": "PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice...",
"keywords": "Nasdaq:PYXS, Pyxis Oncology",
"snippet": "PYX-201 Phase 1 trial clinical readout on track for fall of 2024\n\n\n\nExecutive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice Pr...",
"url": "https://www.globenewswire.com/news-release/2024/05/14/2881275/0/en/Pyxis-Oncology-Provides-Corporate-Update-and-Reports-Financial-Results-for-First-Quarter-2024.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/d3b77f06-3f52-42af-8f38-e3fda9c8025b",
"language": "en",
"published_at": "2024-05-14T11:30:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "MGNX",
"name": "MacroGenics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 6.376695,
"sentiment_score": 0,
"highlights": [
{
"highlight": "led to acquisition by Amgen for $2.7B) with Vectibix® (panitumumab); on behalf of Peregrine a deal with Oncologie Inc. for clinical Phase III level bavituximab; on behalf of Zosano Pharmaceutical with Asahi Kasei Pharma Corporation (AKP) Asahi Kasei Pharma Corporation (AKP) on ZP-PTH®; on behalf of Raven Biotechnologies with B7-H3 & B7-H4 mAbs with <em>Macrogenics</em>",
"sentiment": 0,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "e8718e61-d6fd-4479-9d7e-89370233c0e0",
"title": "MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman",
"description": "MGNX Investors with Substantial Losses Encouraged to Contact Hagens Berman...",
"keywords": "Hagens Berman Sobol Shapiro LLP, Class Action",
"snippet": "SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your lo...",
"url": "https://www.globenewswire.com/news-release/2024/05/13/2880763/32716/en/MacroGenics-MGNX-Stock-Crashes-After-Reporting-Patient-Deaths-in-TAMARACK-Study-Hagens-Berman.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/51670c91-d369-4a8c-8102-d393de9f6d19",
"language": "en",
"published_at": "2024-05-13T16:30:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "MGNX",
"name": "MacroGenics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 80.939285,
"sentiment_score": 0.03345,
"highlights": [
{
"highlight": "SAN FRANCISCO, May 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges <em>MacroGenics</em>, <em>Inc</em>. (<em>NASDAQ</em>: <em>MGNX</em>) investors who suffered substantial losses to submit your losses now.\n\n\n\nVisit: www.hbsslaw.com/investor-fraud/mgnx\n\nContact the Firm Now: [email protected]\n\n844-916-0895\n\n<em>MacroGenics</em>, <em>Inc</em>.",
"sentiment": -0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "(MGNX) Investigation:\n\nThe investigation currently focuses on the propriety of <em>MacroGenics</em>’ statements about certain data from its Phase 2 TAMARACK study for its antibody-drug conjugate MGC018 (“vobra duo”) in patients with metastatic castration-resistant prostate cancer (“mCRPC”).",
"sentiment": -0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "On Apr. 3, 2024, <em>MacroGenics</em> announced Phase 2 TAMARACK interim safety data as contained in its abstract submitted to the American Society of Clinical Oncology on Feb. 6, 2024. The company said “[p]reliminary safety data from TAMARACK suggest that reducing the dose and frequency of vobra duo improves its safety and tolerability in men with mCRPC.”",
"sentiment": 0.8807,
"highlighted_in": "main_text"
},
{
"highlight": "This news drove the price of <em>MacroGenics</em> shares up $4.11 (or up about 30%) on Apr. 4, 2024.\n\nHowever, the optimism was short-lived. On May 10, 2024, <em>MacroGenics</em> revealed that 5 patients in the study died.",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "In addition, SeekingAlpha reported that “Stifel was quick to downgrade <em>MacroGenics</em> (MGNX) after the TAMARACK readout, which, according to the firm, raised concerns over the drug’s safety and tolerability and appeared vastly different from previously disclosed abstract results.”",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "“We’re investigating whether <em>MacroGenics</em> may have misled investors about its Phase 2 TAMARACK interim safety data,” said Reed Kathrein, the Hagens Berman partner leading the investigation.",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "If you invested in <em>MacroGenics</em> and have substantial losses submit your losses now »\n\nIf you’d like more information about the <em>MacroGenics</em> investigation, read more »\n\nAbout Hagens Berman\n\nHagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability.",
"sentiment": -0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "<em>MacroGenics</em> (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens Berman",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "MGNX",
"total_documents": 2,
"sentiment_avg": 0.016724999994039536
}
]
}
Other details
Exchange
- NASDAQ Stock Exchange
- equity
- Healthcare
- us